Key result
p53 prevents doxorubicin-induced cardiac dysfunction and mtDNA depletion, highlighting mitochondrial markers for cardiomyopathy prognosis.
Answers are grounded in this paper and cite their sources.
Shows p53 protects against doxorubicin-induced cardiomyopathy, suggesting new biomarkers for monitoring.
prevented the mtDNA depletion and cardiac dysfunction. These findings suggest that loss of mtDNA contributes to cardiomyopathy pathogenesis induced by doxorubicin administered on a schedule simulating that in the clinics. Given a similar mtDNA protection role of p53 in doxorubicin-treated human induced pluripotent stem cell (iPSC)-derived cardiomyocytes, the mitochondrial markers associated with cardiomyopathy development observed in blood and skeletal muscle cells may have prognostic utility.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied Doxorubicin cardiotoxicity. p53 was evaluated on mtDNA depletion and cardiac dysfunction. p53 prevents doxorubicin-induced mtDNA depletion and cardiac dysfunction, suggesting mitochondrial markers in blood and skeletal muscle may have prognostic utility for cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: